Waters Corp Highlights BD Bioscience Deal and Five-Year Turnaround at JP Morgan
Waters Corporation CEO Udit Batra at the 44th J.P. Morgan Healthcare Conference reviewed its five-year turnaround boosting commercial strength and innovation, and detailed the acquisition of BD’s Bioscience and Diagnostics business. He also offered guidance on expected value creation and strategic financial targets for the next few years.
1. Five-Year Transformation Fuels Commercial and Innovation Strength
Over the past five years, Waters Corporation has executed a strategic transformation that has bolstered its commercial capabilities, revitalized its innovation pipeline and positioned the company to enter fast-growing adjacencies. Management reports investing approximately 10% of annual product sales into R&D, enabling the conversion of complex instrumentation into turnkey systems for high-volume regulated applications. As of today, Waters has more than 170,000 analytical and life-science systems installed in customer laboratories worldwide, a testament to the success of its customer-centric development approach.
2. Acquisition of BD Bioscience & Diagnostics Business Expands Footprint
In early 2024, Waters completed its acquisition of Becton Dickinson’s Bioscience & Diagnostics business for $5.2 billion, marking the company’s largest deal in its history. The transaction adds a complementary portfolio of cell analysis and diagnostic platforms and is expected to contribute approximately $600 million in annual revenue at close. Management projects run-rate cost synergies of $75 million by the end of the first full year post-close, and the deal enriches Waters’ entry into adjacent markets with higher growth profiles than its legacy chromatography and mass spectrometry segments.
3. Strategic and Financial Outlook Targets Sustainable Value Creation
Looking ahead, CEO Udit Batra outlined a multi-year plan to drive double-digit adjusted earnings-per-share growth through a combination of organic innovation, cross-selling opportunities and disciplined M&A. The company expects to generate mid-teens operating margins by 2026, up from 13.8% in FY 2023, supported by productivity initiatives and ongoing R&D leverage. Free cash flow conversion is targeted at 90% of net income, underpinning a commitment to boost the dividend at a compound annual rate of at least 8% and maintain an investment-grade balance sheet.
4. Continued R&D Investment Underpins Long-Term Competitive Advantage
Waters plans to sustain R&D spending at around 10% of product revenues, with an emphasis on digital analytics, software-enabled workflows and nanoflow mass spectrometry. This level of reinvestment is designed to expand Waters’ addressable market beyond traditional analytical chemistry into adjacent fields such as cell therapy characterization and biomarker discovery. The company currently has more than 450 projects in development, including two new instrument platforms slated for launch in 2025 and 2026 that target rapid, high-throughput testing in regulated environments.